3 stories this morning, for surgeons and the people who support them.
- Stryker makes a roughly $400 million preferred equity investment in CMR Surgical, with an exclusive option to buy all of it, and becomes exclusive U.S. sales agent for the Versius soft-tissue robot — Stryker press release datelined Portage, Mich. and Cambridge, England, October 12, 2026: approximately $400 million (GBP 300 million) preferred equity investment in CMR Surgical; exclusive option to acquire 100% of CMR's outstanding equity in the future, subject to the agreement's terms (price and timing not disclosed); Stryker becomes exclusive U.S. sales agent for the Versius portfolio while CMR keeps development and commercialization outside the U.S.; Andy Pierce (Group President, Medsurg and Neurotechnology) joins CMR's board; Pierce calls soft-tissue robotics 'a high-growth adjacency and a natural extension of Stryker's strengths in endoscopy, visualization and enabling technologies' and cites hospitals and ASCs; subject to regulatory approvals and customary closing conditions. Second source: Ortho Spine News, October 12, 2026. Context: Versius received FDA De Novo marketing authorization in October 2024 for cholecystectomy in adults 22 and older (CMR Surgical release; Vattikuti Foundation, Oct 21, 2024). CMR raised $600M in a 2021 Series D led by SoftBank Vision Fund 2 and more than $200M in 2025 debt and equity to fund its U.S. launch (Fierce Biotech). Stryker's Mako robot is orthopaedic only. Source
- Shoulder Innovations begins a limited user release of InSet Go, its next-generation inset anatomic glenoid, after a first case at University Hospitals Cleveland — PR Newswire release, Grand Rapids, Mich., October 8, 2026 (Ortho Spine News; also reprinted on ariva.de): Shoulder Innovations (NYSE: SI) began a limited user release of the InSet Go glenoid for anatomic shoulder arthroplasty after the first case, by Robert Gillespie, MD, at University Hospitals Cleveland Medical Center. Keeps the InSet principle of seating the component within a rim of cortical bone, with fewer surgical steps and 'the potential for reduced procedure times' (no figure given); adds IP covering the articular surface and InSet PLUS augmented configurations for bone loss. Full commercial introduction expected 'over the coming quarters'. No clearance number stated. Company context from its Aug 6, 2026 Q2 release (SEC 8-K Ex. 99.1): Q2 net revenue $17.2M (+56%), 2,238 implant systems sold (~+50%), ASP $7,674, full-year 2026 guidance raised to $67M to $69M. Prior Shoulder Innovations items covered 2026-09-09 (Catalyst patent settlement) and 2026-09-11 (N-22 humeral head); InSet Go is a separate product. Source
- Bone & Joint Journal, Belgian single-centre propensity-matched study of 780 uncemented THAs: dual mobility had about one-tenth the dislocations of ceramic-on-ceramic but three to five times the femoral periprosthetic fractures — Komat M, et al. Bone Joint J. 2026 Oct 1;108-B(10):1231-1237; doi 10.1302/0301-620X.108B10.BJJ-2025-1810.R2; indexed in PubMed October 9, 2026 (PMID 42853085). EpiCURA Hospital, Saint-Ghislain, and Université Libre de Bruxelles. 1,415 uncemented THAs, 2017 to 2024: 425 dual mobility vs 990 ceramic-on-ceramic. Periprosthetic fracture 4.0% (17/425) vs 0.8% (8/990), OR 4.8 (95% CI 1.86 to 12.4); after propensity matching (260 vs 520) OR 3.5 (95% CI 1.3 to 8.6). Dislocation after matching 0.4% (1/260) vs 4.0% (21/520), OR 0.09. Femoral neck fracture as the indication independently raised the risk of both fracture and dislocation; no significant interaction between bearing type and indication. Authors' conclusion is hedged ('may be associated'). Retrospective design; no conflicts declared. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.